NCT05548777View on ClinicalTrials.gov

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

CompletedOBSERVATIONAL

Enrollment

5,480

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions

Anticoagulant-related Major Bleed

Interventions

DRUG

Andexanet alfa

Andexanet alfa

DRUG

4F-PCC

Four-Factor Prothrombin Complex Concentrate (4F-PCC)

Trial Locations (1)

91301

Research Site, Agoura Hills

Sponsors

Lead Sponsor

Collaborators (1)

Outcomes Insights

All Listed Sponsors

collaborator

Outcomes Insights

UNKNOWN

lead

AstraZeneca

INDUSTRY